Prognostic value of pretreatment peripheral blood markers in paranasal sinus cancer: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio

Abstract

High pretreatment NLR and PLR are associated with poor prognosis in patients affected by epithelial advanced-stage SNC. © 2016 Wiley Periodicals, Inc. Head Neck 39: 730-736, 2017.

Neutrophil‐to‐lymphocyte ratio as a prognostic indicator in head and neck cancer: A systematic review and meta‐analysis

“…Data from 11 studies were synthesized in the meta‐analysis for NLR and OS in patients with head and neck cancer (Table ) . An elevated NLR value was found to be significantly associated with poorer OS with HR of 1.51 (95% CI 1.32‐1.73; P < .001).…”

“…The PRISMA flow chart of the systematic review can be found in Figure . An initial search done using the search strategy (Supporting Materials) obtained an initial 900 results.…”

“…We attempted contacting authors if the information in their article was not sufficiently detailed to be extracted, such as details on adjusted regression analysis, information on NLR cutoff, or the method of obtaining the cutoff . If the HR for OS was reported as an HR of a patient with NLR below a specific cutoff experiencing the endpoint of death (vs HR of a patient with NLR above a specific cutoff experiencing the endpoint of death), we took the reciprocal of the reported HR in order to make it comparable with the other studies …”

Platelet count and platelet‐lymphocyte ratio as prognostic markers for head and neck squamous cell carcinoma: Meta‐analysis

“…A meta-analysis of the association between platelet count and prognosis of patients with HCC showed that thrombocytopenia is associated with poor survival. Turri-Zanoni et al 66 reported that higher PLR and NLR were associated with poor prognoses of paranasal sinus cancers, including adenocarcinoma, other carcinomas, olfactory neuroblastoma, and melanoma. However, HCC is generally accompanied by liver cirrhosis, which eventually causes thrombocytopenia.…”

“…Inclusion criteria regarding tumor site, treatment modalities, and clinical stage were different. 66,68 Sixth, the cutoff values for platelet count or PLR were inconsistent among individual studies, which could have resulted in heterogeneity. Some studies excluded patients with conditions that could affect hematologic markers (eg, acute inflammation and autoimmune disease), 34,35,[43][44][45]51 although other studies did not use such criteria.…”